COVID-19
Excerpt from the Article: Ultrasound could be a disruptive tool in the fight against COVID-19, according to new research. A recent study published in the Journal of the Mechanics and Physics of Solids has found that the structure of the coronavirus may be vulnerable to the vibrations of an ultrasound with frequencies commonly used in…
Read More
Excerpt from the Press Release: SAN DIEGO, March 11, 2021 /PRNewswire/ — Persephone Biosciences Inc., a privately held, data-driven microbiome-focused biotechnology company, today announced the initiation of the VOICES clinical study to determine the impact of gut microbiome composition and function on the immune system and efficacy of COVID-19 vaccination. VOICES (Vaccine Observation to Include all…
Read More
Excerpt from the Press Release: PARIS and LEXINGTON, Mass., March 12, 2021 (GLOBE NEWSWIRE) — Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the start of the Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2, the…
Read More
Excerpt from the Press Release: SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced biomarker results from its Phase 2 double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participants have been dosed in the Phase 1 study of mRNA-1283, the Company’s next generation COVID-19 vaccine candidate. “We are pleased to begin this Phase 1 study of our…
Read More
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–VeriSIM Life has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR)grant for $255,908 to conduct research and development (R&D) work onrapid repurposing and translation of approved and investigational drugs for COVID-19 using its patented artificial intelligence (AI) driven biosimulation platform, BIOiSIM. VeriSIM Life has…
Read More
Excerpt from the Press Release: PRINCETON, N.J., March 4, 2021 /PRNewswire/ — Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for CiVax™ (heat stable COVID-19 vaccine program) demonstrating rapid-onset,…
Read More Excerpt from the Article: It’s rare for current events to inform the work of scientists as acutely as during a pandemic. In February 2020, a team of scientists from the international initiative of the Human Cell Atlas, including scientists at the Broad Institute of MIT and Harvard, sifted through a dataset on healthy human cells…
Read More
Excerpt from the Article: As the COVID-19 pandemic enters its second year, scientists are still working to understand how the SARS-CoV-2 strain evolved, and how it became so much more dangerous than other coronaviruses, which humans have been living alongside for millennia. Virologists and epidemiologists worldwide have speculated for months that a protein called ORF8…
Read More
Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing. This…
Read More